Patents by Inventor Derek McLaren

Derek McLaren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240094202
    Abstract: Irritable Bowel Syndrome (IBS) is a multifactorial disorder characterized by pain, bloat, and changes in bowel movements, where different bacteria in the gut microbiome potentially influence some or all of the related symptoms. However, IBS is extremely heterogenous, suggesting a need to identify relationships between groups of bacteria in the gut microbiome and specific IBS-related symptoms. RS consumption significantly altered the microbiome while improving several measures of IBS. The use of RS by those needing to reduce the IBS-related symptoms, including those diagnosed with IBS, can be guided by simultaneously measuring changes in select genera in the microbiome.
    Type: Application
    Filed: October 14, 2021
    Publication date: March 21, 2024
    Inventors: Derek McLaren, Earl McLaren
  • Publication number: 20220226400
    Abstract: Elucidating the relationship between specific intestinal bacteria, dietary intake, and the health of the host remains a primary goal for gut microbiome research. Prebiotics, substrates that are selectively used by microorganisms to promote the health of the host, present an appealing therapeutic option. We performed correlation analysis to identify relationships between health parameters and populations of gut bacteria in participants from a randomized, placebo-controlled clinical trial testing the effects of a prebiotic digestion resistant potato starch (DRS; MSPrebiotic®). This study focused on the abundance of Parasutterella (phylum Proteobacteria), which tended to increase in the gut microbiome of individuals consuming DRS. Increases in Parasutterella were correlated with reductions in low-density lipoprotein (LDL) levels in participants consuming DRS but not placebo.
    Type: Application
    Filed: April 22, 2020
    Publication date: July 21, 2022
    Inventors: Derek McLaren, Earl McLaren
  • Publication number: 20210340590
    Abstract: Individuals consuming a prebiotic and who displayed improvements in blood glucose and/or insulin levels also displayed a decrease in the levels of the non-butyrate-producing Firmicutes genus of bacteria Sporacetigenium. Increasing levels of butyrate-producing Firmicutes genera were not consistently correlated with improvements in metabolism in response to prebiotic consumption. In the general population, Sporacetigenium levels are positively correlated with insulin levels.
    Type: Application
    Filed: September 12, 2019
    Publication date: November 4, 2021
    Inventors: Derek McLaren, Earl McLaren
  • Patent number: 11058711
    Abstract: Consumption of resistant potato starch results in changes to the gut microbiome in elderly adults, resulting in a healthier gut microbiome profile. Furthermore, consumption of resistant potato starch stimulates an increase in Bifidobacterium abundance in all individuals and also reduces levels of E. coli and Shigella. Furthermore, consumption of MSPrebiotic® increased the relative ratio of butyrate in the elderly and significantly reduced the use of stool softeners in the elderly.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: July 13, 2021
    Assignee: McPharma Biotech Inc.
    Inventors: Derek McLaren, Earl McLaren
  • Patent number: 10632142
    Abstract: Resistant potato starch is demonstrated to have therapeutic effects on ulcerative colitis through attenuation of diarrhea, repair or reduction of intestinal damage, modulation of local gene expression and treatment of intestinal dysbiosis. Administering resistant potato starch in pigs pre-exposed to colitis improved fecal score although use of resistant potato starch as a preventive measure did not prevent diarrhea associated with induction of colitis and in fact impaired the ability of the resistant potato starch to treat ulcerative colitis.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: April 28, 2020
    Assignee: McPharma Biotech Inc.
    Inventors: Derek McLaren, Earl McLaren
  • Publication number: 20190262382
    Abstract: Resistant potato starch is demonstrated to have therapeutic effects on ulcerative colitis through attenuation of diarrhea, repair or reduction of intestinal damage, modulation of local gene expression and treatment of intestinal dysbiosis. Administering resistant potato starch in pigs pre-exposed to colitis improved fecal score although use of resistant potato starch as a preventive measure did not prevent diarrhea associated with induction of colitis and in fact impaired the ability of the resistant potato starch to treat ulcerative colitis.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 29, 2019
    Inventors: Derek McLaren, Earl McLaren
  • Publication number: 20190256614
    Abstract: Described herein is the use of resistant potato starch as an effective dietary supplement offering protection against multiple metabolic risk factors that are associated with cardiovascular disease and diabetes, including High Density Lipoprotein levels, blood glucose levels and insulin resistance.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Inventors: Derek McLaren, Earl McLaren
  • Publication number: 20190224230
    Abstract: Consumption of resistant potato starch results in changes to the gut microbiome in elderly adults, resulting in a healthier gut microbiome profile. Furthermore, consumption of resistant potato starch stimulates an increase in Bifidobacterium abundance in all individuals and also reduces levels of E. coli and Shigella. Furthermore, consumption of MSPrebiotic® increased the relative ratio of butyrate in the elderly and significantly reduced the use of stool softeners in the elderly.
    Type: Application
    Filed: July 6, 2017
    Publication date: July 25, 2019
    Inventors: Derek McLaren, Earl McLaren
  • Patent number: 9861654
    Abstract: Low levels of resistant potato starch, for example, 0.5-1.0% of total diet, have a beneficial effect on post-weaning diarrhea, infectious diarrhea and gastrointestinal stresses associated with weaning. Also described are capsules and tablets of resistant potato starch, and methods for making said capsules and tablets.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: January 9, 2018
    Inventors: Derek McLaren, Earl McClaren
  • Publication number: 20160193243
    Abstract: Described herein is the use of resistant potato starch as an effective dietary supplement offering protection against multiple metabolic risk factors that are associated with cardiovascular disease and diabetes, including High Density Lipoprotein levels, blood glucose levels and insulin resistance.
    Type: Application
    Filed: August 7, 2014
    Publication date: July 7, 2016
    Inventors: Derek McLaren, Earl McLaren
  • Publication number: 20150250814
    Abstract: Low levels of resistant potato starch, for example, 0.5-1.0% of total diet, have a beneficial effect on post-weaning diarrhea, infectious diarrhea and gastrointestinal stresses associated with weaning. Also described are capsules and tablets of resistant potato starch, and methods for making said capsules and tablets.
    Type: Application
    Filed: September 6, 2013
    Publication date: September 10, 2015
    Applicant: MCPHARMA BIOTECH INC.
    Inventors: Derek McLaren, Earl McLaren